Advanced search
Publication Cover
Expert Review of Neurotherapeutics Volume 17, 2017 - Issue 12
Submit an article Journal homepage
275
Views
10
CrossRef citations to date
0
Altmetric
Drug Profile

Valbenazine for the treatment of tardive dyskinesia

Thomas MüllerDepartment of Neurology, St. Joseph Hospital Berlin-Weissensee, Berlin, GermanyCorrespondence[email protected] [email protected]
View further author information
Pages 1135-1144 | Received 26 Jul 2017, Accepted 27 Sep 2017, Published online: 12 Oct 2017

Citations (10)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Christian Cheng, Nicholas Brownstone & John Koo. (2022) Treatment of tardive dyskinesia: a review and update for dermatologists managing delusions of parasitosis. Journal of Dermatological Treatment 33:3, pages 1319-1323.
Read now
Benjamin J. Dorfman & Joohi Jimenez-Shahed. (2021) Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia. Expert Review of Neurotherapeutics 21:1, pages 9-20.
Read now

Articles from other publishers (8)

Yuma Yokoi, Hiroko Kashiwagi, Daisuke Funada, Shingo Yamashita & Chika Kubota. (2023) Depression and suicidality with VMAT2 inhibitors in tardive dyskinesia A signal detection from the FDA Adverse Events Reporting System. Psychiatry and Clinical Neurosciences Reports 2:1.
Crossref
Yifei Yang, Dawei Yu, Xiaoyin Zhu, Guangying Du, Wenyan Wang, Fangxia Zou, Hongbo Wang, Rui Zhang, Liang Ye & Jingwei Tian. (2021) Synthesis and analysis of dihydrotetrabenazine derivatives as novel vesicular monoamine transporter 2 inhibitors. European Journal of Medicinal Chemistry 224, pages 113718.
Crossref
Arjun Tarakad. (2020) Clinical Rating Scales and Quantitative Assessments of Movement Disorders. Neurologic Clinics 38:2, pages 231-254.
Crossref
Alyssa M. Peckham & Jessica A. Nicewonder. (2018) VMAT2 Inhibitors for Tardive Dyskinesia—Practice Implications. Journal of Pharmacy Practice 32:4, pages 450-457.
Crossref
Laurent Ettouati, Zoé Senta-Loys, Sandrine Bourgeois, Bernard Fenet, Marc Le Borgne & Hatem Fessi. (2019) Behaviour of Tetrabenazine in Acid Medium: Reassessment and Impact on Formulation. Pharmaceutics 11:1, pages 44.
Crossref
Arjun Tarakad & Joohi Jimenez-Shahed. (2018) VMAT2 Inhibitors in Neuropsychiatric Disorders. CNS Drugs 32:12, pages 1131-1144.
Crossref
Karen Frei, Daniel D. Truong, Stanley Fahn, Joseph Jankovic & Robert A. Hauser. (2018) The nosology of tardive syndromes. Journal of the Neurological Sciences 389, pages 10-16.
Crossref
Nicki Niemann & Joseph Jankovic. (2018) Treatment of Tardive Dyskinesia: A General Overview with Focus on the Vesicular Monoamine Transporter 2 Inhibitors. Drugs 78:5, pages 525-541.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.